Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Show more

2001 Market Street, Suite 200, Philadelphia, PA, 19103, United States

https://www.contexttherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

197.5M

52 Wk Range

$0.49 - $3.62

Previous Close

$2.15

Open

$2.14

Volume

407,958

Day Range

$2.08 - $2.19

Enterprise Value

143.3M

Cash

54.53M

Avg Qtr Burn

-11.43M

Insider Ownership

1.18%

Institutional Own.

81.31%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CT-202 Details Cancer, solid tumor/s	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CT-95 Details Solid tumor/s	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTIM-76 Details Testicular cancer, Endometrial cancer, Ovarian cancer	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.